Here are the 10-K annual reports from Pro-Dex Inc New (PDEX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PDEX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PDEX filings page.
Pro-Dex, Inc. (PDEX) reported strong growth for the year ended June 30, 2026, with net sales of $77.5 million, up 16% from 2025, and net income of $13.7 million, up from $9.0 million. Gross margin improved to 31%, and operating income rose to $13.0 million (17% of sales).
Growth was driven by a 30% increase in medical device revenue to $62.1 million, particularly orthopedic products for its largest customer following a next‑generation handpiece launch, while repair revenue declined 33% to $12.5 million as that customer transitioned away from legacy devices. Pro-Dex acquired Advanced Precision Machining, LLC (APM) in February 2026, adding aerospace and defense machining capabilities and contributing to a 76% increase in industrial and scientific sales. Other income benefited from realized gains on the Monogram investment, and the company generated $7.2 million of operating cash flow, ending the year with $8.2 million in cash and $40.3 million of working capital. Backlog was $32.9 million, down from $50.4 million, with most expected to ship in fiscal 2027. The company repurchased 79,898 shares for $3.4 million and had 3,203,334 shares outstanding as of September 2, 2026.
Pro-Dex, Inc. filed its Form 10-K for fiscal 2025 describing operations in medical and scientific devices, including segment sales, balance sheet highlights, financing activity, and governance disclosures. Repairs revenue rose to $18,586 (up from $16,505), CMF sales totaled $9,943 (down ~4%), and thoracic sales increased by $1.3 million to $4.3 million. Operating income improved to $10,689 from $7,173. Investments carried net unrealized gains of $3.3 million at June 30, 2025 versus $1.8 million a year earlier. The company purchased a property for $6.5 million financed with a $5.2 million Property Loan. The revolving credit line was increased to $11.0 million and term loans carry maturities through 2029–2030 with a $3.1 million balloon due at maturity. Share repurchases totaled 130,148 shares at $3.5 million in fiscal 2025. The filing discloses customer concentration (major customer represented ~75% of sales) and notes cybersecurity risk management and standard risk-factor disclosures.